Market Opportunities

SLE

Our lead compound is being developed to treat systemic lupus erythematosus (SLE), an autoimmune disease in which the immune system mistakenly attacks normal tissues in the body. Clinical presentation and symptoms vary widely and can include fatigue, arthritis, chest pain, kidney damage, and neurologic symptoms. Patients with SLE face a higher risk of cardiovascular illness and death.

mTOR inhibitors have been shown to deliver impressive efficacy both in clinical models and in a clinical study, but adverse events limit utility. In preclinical animal models of lupus, TAM-01 has shown a strong efficacy profile while delivering a superior safety profile, one that demonstrates TAM-01s potential to address unmet need in SLE.

Oncology

In many cancers, mTORC1 and mTORC2 activity is elevated, and reducing mTOR activity has proven an important therapeutic strategy in oncology, with several rapalogs currently approved for use in a range of cancers. Efficacy seen to date, however, leaves significant unmet need.

Mount Tam’s compounds TAM-01 and TAM-03, with unique mTOR inhibitory profiles, have been tested against a range of cancer cell lines and have shown promising, differentiated activity in a number of important cancer types. We are continuing to advance our oncology Discovery program with the goal of bringing to the clinic compounds that can improve outcomes in cancer patients, and we are excited by their potential to make a real difference.

Other Rare Diseases

Along with our program in SLE, we are focused on addressing a range of rare diseases where mTORC1 activity is known to be elevated. These include serious neurodegenerative diseases including Parkinson's and Huntington's disease along with several rare genetic disorders where inhibiting mTORC1 activity is an important therapeutic target. With a well grounded expectation of a superior AE profile, a potent and selective mTORC1 inhibitor has the potential to address these diseases with the tolerability profile that will be required for chronic dosing in these populations.

Copyright © 2017 / All rights reserved.Mount Tam Biomedical / Notices & Disclaimers